Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42771   clinical trials with a EudraCT protocol, of which   7044   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-001306-33
    Sponsor's Protocol Code Number:PQR309-005
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2017-01-04
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2015-001306-33
    A.3Full title of the trial
    Open-label, non-randomized, phase 2 study evaluating efficacy and safety of PQR309 in patients with relapsed or refractory primary CNS lymphoma
    Estudio abierto, no aleatorio, de fase 2, para evaluar la eficacia y la seguridad de PQR309 en pacientes con linfoma primario del SNC refractario o recidivante
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Phase 2 study evaluating efficacy and safety of PQR309 in patients with relapsed or refractory primary CNS lymphoma
    Estudio de fase 2 para evaluar la eficacia y la seguridad de PQR309 en pacientes con linfoma primario del SNC refractario o recidivante
    A.4.1Sponsor's protocol code numberPQR309-005
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorPIQUR Therapeutics AG
    B.1.3.4CountrySwitzerland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportPIQUR Therapeutics AG
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationPIQUR Therapeutics AG
    B.5.2Functional name of contact pointChief Operating Officer
    B.5.3 Address:
    B.5.3.1Street AddressHochbergerstrasse 60C
    B.5.3.2Town/ cityBasel
    B.5.3.3Post code4057
    B.5.3.4CountrySwitzerland
    B.5.6E-mailfrances.betts@piqur.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePQR309
    D.3.2Product code PQR309
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNot available yet
    D.3.9.1CAS number 1225037-39-7
    D.3.9.2Current sponsor codePQR309
    D.3.9.3Other descriptive name5-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)-2-pyridinamine
    D.3.9.4EV Substance CodeSUB172213
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePQR309
    D.3.2Product code PQR309
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNot available yet
    D.3.9.1CAS number 1225037-39-7
    D.3.9.2Current sponsor codePQR309
    D.3.9.3Other descriptive name5-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)-2-pyridinamine
    D.3.9.4EV Substance CodeSUB172213
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number80
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Relapsed or refractory primary CNS lymphoma (PCNSL)
    Linfoma primario del SNC refractario o recidivante
    E.1.1.1Medical condition in easily understood language
    Relapsed or refractory primary central nervous system lymphoma
    Linfoma primario del sistema nervioso central refractario o recidivante
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.0
    E.1.2Level LLT
    E.1.2Classification code 10036685
    E.1.2Term Primary central nervous system lymphoma
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the clinical efficacy of PQR309 in the treatment of patients with relapsed or refractory primary CNS lymphoma.
    Evaluar la eficacia clínica de PQR309 en el tratamiento de pacientes con LPSNC recidivante o refractario.
    E.2.2Secondary objectives of the trial
    To evaluate:
    - Overall safety and tolerability of PQR309
    - Overall clinical efficacy of PQR309
    - Pharmacokinetics (PK) of PQR309 in plasma
    Evaluar la:
    - Seguridad general y tolerancia de PQR309
    - Eficacia clínica general de PQR309
    - Farmacocinética (PC) de PQR309 en plasma
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. ≥ 18 years of age.
    2. Patient with histologically/cytologically confirmed PCNSL at first progression.
    3. Relapsed or refractory PCNSL demonstrated by cranial MRI.
    4. Presence of at least one lesion of bi-dimensionally measurable disease on baseline MRI with a contrast-enhancing tumor of at least 1 cm (10 mm) in the longest diameter.
    5. Maximum two prior systemic therapy regimens excluding high dose chemotherapy at first relapse.
    6. If receiving corticosteroids, patients must have been on a stable or decreasing dose of corticosteroids and no more than 8 mg dexamethasone (or equivalent) for at least 5 days prior to date of enrollment.
    7. Karnofsky Performance Score (KPS) ≥ 70%.
    8. More than 4 weeks from any investigational agent (at the judgment of the investigator and in agreement with lead investigator and PIQUR).
    Adequate haematological, liver and renal function defined as follows: absolute neutrophil count (ANC) ≥ 1.5x109/l, platelets ≥ 100x109/l, hemoglobin ≥ 100g/L. Total bilirubin ≤ 1.5 times the upper limit of normal (ULN). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN. Serum Creatinine ≤ 1.5 times ULN.
    9. Able and willing to swallow and retain oral medication.
    10. Female and male patients of reproductive potential must agree to use effective contraception from screening until 90 days after discontinuing study treatment.
    11. Willing and able to sign the informed consent and to comply with the protocol for the duration of the study.
    1. ≥ 18 años de edad.
    2. Paciente con LPSNC confirmado histológicamente/citológicamente
    3. LPSNC recidivante o refractario demostrada mediante RM craneal.
    4. Presencia de al menos una lesión de enfermedad bimensionalmente medible en la IRM basal con un tumor que aumenta la densidadal menos 1 cm (10 mm) en el diámetro mayor.
    5. Máximo de dos regímenes de terapia sistémica previa excluyendo la quimioterapia de dosis alta en la primera recaída.
    6. En caso de recibir corticosteroides, los pacientes deben haber recibido una dosis estable o decreciente de corticosteroides y no más de 8 mg de dexametasona (o equivalente) durante al menos 5 días antes de la fecha de inclusión(véase la sección 12.4 para definición de fecha de inclusión).
    7. Escala de Karnofsky (KPS) ≥ 70%.
    8. Más de 4 semanas de de ausencia de exposición a cualquier otro agente de investigación (a juicio del investigador y de acuerdo con el investigador coordinador y PIQUR).
    9. Función hematológica, hepática y renal adecuadas definidas como sigue:
    Recuento absoluto de neutrófilos (RAN) ≥ 1,5x109/l, plaquetas ≥ 100x109/l, hemoglobina ≥ 100 g/L
    Bilirrubina total ≤ 1,5 veces el límite superior del intervalo normal (LSN). Alanina aminotransferasa (ALT) y aspartato aminotransferasa (AST) ≤ 2,5 veces el LSN
    Creatinina sérica ≤ 1,5 veces el LSN.
    10. Capaz y dispuesto a tragar y retener la medicación oral.
    11. Los pacientes de sexo femenino y masculino con potencial reproductivo deben aceptar el uso de métodos anticonceptivos eficaces desde el cribado hasta 90 días después de la suspensión del tratamiento del estudio.
    12. Dispuesto y capaz de firmar el consentimiento informado y de cumplir el protocolo durante el estudio.
    E.4Principal exclusion criteria
    1. Secondary CNS lymphoma or chronic immunosuppresion-associated CNS lymphoma.
    2. Previous allogeneic hematopoietic stem cell transplant (HSCT transplant).
    3. Previous whole brain radiotherapy (WBRT).
    4. Other concomitant anti-tumor therapy as determined by the study team.
    5. Patients unable to undergo contrast-enhanced MRI.
    6. Prior treatment with a PI3K inhibitor, AKT inhibitor, or mTOR inhibitor.
    7. Patient taking enzyme-inducing anti-epileptic drug (EIAED) < 7 days of the first dose of PQR309.
    8. Patient is taking a drug with known risk to promote QT prolongation and Torsades de Pointes.
    9. Patient is currently using herbal preparations or medications. Patient should stop using herbal medications 7 days prior to the first dose of the study drug.
    10. Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (e.g. risk of doing harm to self or others), or patients with active severe personality disorders.
    11. Anxiety ≥CTC AE grade 3.
    12. Patient has an uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, known HIV infection, chronic liver disease, chronic renal disease, pancreatitis, chronic pulmonary disease, active cardiac disease or cardiac dysfunction, interstitial lung disease, active autoimmune disease, uncontrolled diabetes, neuropsychiatric or social situations that would limit compliance with the study requirements.
    13. Presence of gastrointestinal disease or any other condition that could interfere significantly with the absorption of the study drug.
    14. Concomitant treatment with medicinal products that increase the pH (reduce acidity) of the upper gastrointestinal tract, including, but not limited to, proton-pump inhibitors (e.g. omeprazole), H2-antagonists (e.g. ranitidine) and antacids. Patients may be enrolled in the study after a washout period sufficient to terminate their effect.
    15. Patient has a history of invasive malignancy other than PCNSL. Patients are eligible if they are disease free for at least 3 years and deemed to be at low risk for recurrence by the Investigator. Patients diagnosed with cervical cancer in situ, basal cell or squamous cell carcinoma of the skin and treated within the past 3 years are eligible.
    16. Women who are pregnant or breast feeding.
    17. Women able to conceive and unwilling to practice an effective method of birth control from screening until 90 days after discontinuing study treatment (women of childbearing potential must have a negative serum pregnancy test within 7 days prior to first dose of PQR309).
    18. Fasting glucose > 7.0 mmol/L (126 mg/dL).
    1. Linfoma secundario del SNC o linfoma del SNC asociado con inmunosupresión crónica.
    2. Trasplante previo de células madre hematopoyéticas alogénicas (transplante HSCT).
    3. Radioterapia cerebral total (WBRT) previa.
    4. Otras terapias antitumorales concomitantes según lo determinado por el equipo del estudio.
    5. Pacientes que no pueden someterse a resonancia magnética con contraste.
    6. Tratamiento previo con un inhibidor de PI3K, un inhibidor de AKT o un inhibidor de mTOR.
    7. Pacientes que tomen un fármaco antiepiléptico inductor enzimático (EIAED) <7 días de la primera dosis de PQR309.
    8. Paciente que están tomando un fármaco con riesgo de promover la prolongación del intervalo QT y Torsades de Pointes.
    9. Paciente esté utilizando preparaciones o medicamentos a base de hierbas. El paciente debe dejar de utilizar medicamentos a base de plantas 7 días antes de la primera dosis del medicamento del estudio.
    10. Antecedentes médicos documentados de episodio depresivo mayor activo, trastorno bipolar (I o II), trastorno obsesivo-compulsivo, esquizofrenia, antecedentes de intento de suicidio o ideación suicida, o ideación homicida (es decir, riesgo de daño a uno mismo o a otros) o pacientes con trastornos graves de personalidad activos.
    11. Ansiedad ≥CTC AE grado 3.
    12. El paciente tiene una enfermedad intercurrente no controlada, incluyendo, pero sin carácter limitante, infección continuada o activa, infección por VIH, enfermedad hepática crónica, enfermedad renal crónica, pancreatitis, enfermedad pulmonar crónica, enfermedad cardiaca activa o disfunción cardiaca, enfermedad pulmonar intersticial, enfermedad autoinmune activa, diabetes no controlada, situaciones neuropsiquiátricas o sociales que pudieran limitar el cumplimiento de los requisitos del estudio.
    13. Presencia de enfermedad gastrointestinal o de cualquier otra condición que pudiera interferir significativamente con la absorción del fármaco del estudio.
    14. El tratamiento concomitante con medicamentos que aumentan el pH (reducen la acidez) del tracto gastrointestinal superior, incluyendo pero sin carácter limitativo, inhibidores de la bomba de protones (por ejemplo omeprazol), antagonistas H2 (por ejemplo ranitidina) y antiácidos. Los pacientes pueden ser incluidos en el estudio después de un período de lavado suficiente para terminar su efecto.
    15. El paciente tiene antecedentes de malignidad invasiva que no sea LPSNC. Los pacientes pueden participar si están libres de enfermedad durante al menos 3 años y el investigador considera que el riesgo de recidiva es bajo. Los pacientes diagnosticados con cáncer cervical in situ, carcinoma basocelular o de células escamosas de la piel y tratados en los últimos 3 años también pueden participar.
    16. Mujeres embarazadas o lactantes.
    17. Mujeres capaces de concebir y que no están dispuestas a usar un método anticonceptivo eficaz desde el cribado hasta 90 días después de suspender el tratamiento del estudio (las mujeres en edad fértil deben tener una prueba de embarazo en suero negativa dentro de los 7 días anteriores a la primera dosis de PQR309).
    18. Glucosa en ayunas> 7,0 mmol / L (126 mg / dL).
    E.5 End points
    E.5.1Primary end point(s)
    ORR including complete response (CR), unconfirmed complete (CRu) and partial response (PR) according to the 2005 Response Criteria of the International Primary CNS Lymphoma Collaborative Group (IPCG)
    TRG incluyendo la respuesta completa (RC), respuesta completa sin confirmar (RCsc) y la respuesta parcial (RP) según los Criterios de Respuesta del Grupo Colaborativo Internacional del Linfoma Primario del SNC de 2005
    E.5.1.1Timepoint(s) of evaluation of this end point
    4 and 8 weeks after first intake of PQR309, subsequently every 8 weeks
    A las 4 y 8 semanas del inicio del tratamiento del estudio y cada 8 semanas posteriormente
    E.5.2Secondary end point(s)
    Safety:
    - Incidence and severity of AEs including SAEs
    - Changes in vital signs (pulse rate, blood pressure, body temperature), Karnofsky performance status (KPS), physical examinations, body weight, ECG, PHQ-9 questionnaire and GAD-7 mood scale score
    - Changes of routine laboratory assessments (haematology, blood chemistry, urinalysis)
    - Changes in Mini-Mental State Examination (MMSE) score

    Additional Clinical Efficacy:
    - Time to response (TTR), duration of response (DOR), time to treatment failure (TTF), progression-free survival (PFS) and survival rate at 1 year

    Pharmacokinetics:
    - PQR309 plasma concentration, PK parameters
    Seguridad:
    - Incidencia y severidad de los AA incluyendo AAG
    - Cambios en los signos vitales (pulso, tensión arterial, temperatura corporal), escala de Karnofsky (KPS), exámenes físicos, peso corporal, ECG, cuestionario PHQ-9 y escala de estado de ánimo GAD-7
    - Cambios en las evaluaciones de laboratorio rutinarias (hematología, bioquímica, análisis de orina)
    - Cambios en la miniprueba de estado mental (MMSE)

    Eficacia clínica adicional:
    - Tiempo hasta la respuesta (THR), duración de la respuesta (DR), tiempo hasta el fracaso del tratamiento (TFT), supervivencia sin progresión (SSP) y tasa de supervivencia a 1 año

    Farmacocinética:
    - Concentración en plasma de PQR309, parámetros PC
    E.5.2.1Timepoint(s) of evaluation of this end point
    AE monitoring: at Weeks 1, 2, 3, 4, 6 and 7 (and every three weeks later), and at 30 days after the last dose
    Vital signs: at Screening, at Weeks 1, 2, 3, 4 and 7 (and every three weeks later), at the end of treatment and 30 days after the last dose
    Haematology & Blood chemistry: at Screening, at Weeks 1, 2, 3, 4, 6 and 7 (and every three weeks later), and at 30 days after the last dose
    Urinalysis: at Screning, at Weeks 1, 4 and 7 (and every three weeks later), and the end of treatment
    MMSE: at Screening and at the end of treatment
    PK sampling: at Weeks 1 (Day 1 and 2), 2, 3, 4 and 7 (and every three weeks later) (depending on dosing schedule)
    Vigilancia de AA: a las semanas 1, 2, 3, 4, 6 y 7 (y cada 3 semanas posteriormente), y 30 días después de la finalización del tratamiento
    Signos vitales: al cribado, a las semanas 1, 2, 3, 4 y 7 (y cada 3 semanas posteriormente), al finalización del tratamiento y 30 días después de la finalización del tratamiento
    Hematología & bioquímica: al cribado, a las semanas 1, 2, 3, 4, 6 y 7 (y cada 3 semanas posteriormente), y 30 días después de la finalización del tratamiento
    Análisis de orina: al cribado, a las semanas 1, 4 y 7 (y cada 3 semanas posteriormente), y al finalización del tratamiento
    MMSE: al cribado y al finalización del tratamiento
    Farmacocinética: a las semanas 1 (Día 1 y 2), 2, 3, 4 y 7 (y cada 3 semanas posteriormente) (dependiente de la pauta posológica)
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised Information not present in EudraCT
    E.8.1.2Open Information not present in EudraCT
    E.8.1.3Single blind Information not present in EudraCT
    E.8.1.4Double blind Information not present in EudraCT
    E.8.1.5Parallel group Information not present in EudraCT
    E.8.1.6Cross over Information not present in EudraCT
    E.8.1.7Other Information not present in EudraCT
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Information not present in EudraCT
    E.8.2.2Placebo Information not present in EudraCT
    E.8.2.3Other Information not present in EudraCT
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA29
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Belgium
    Canada
    France
    Germany
    Italy
    Netherlands
    Spain
    Switzerland
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Última visita del último paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months9
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months6
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 18
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 3
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state10
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 43
    F.4.2.2In the whole clinical trial 50
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    All patients enrolled in the study may be treated with PQR309 until unacceptable AE, tumor progression, patient’s request for withdrawal, investigator judgment or death whichever comes first.
    Todos los pacientes incluidos en el estudio se tratan con PQR309 hasta observar AA inaceptables, progresión del tumor, solicitud de retirada del paciente, criterio del investigador o muerte, lo que ocurra primero.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-03-08
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-02-24
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA